Style | Citing Format |
---|---|
MLA | Shahriari M, et al.. "Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains." Avicenna Journal of Medical Biotechnology, vol. 16, no. 4, 2024, pp. 279-283. |
APA | Shahriari M, Shafiee F, Moazen F, Mir Mohammad Sadeghi H (2024). Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains. Avicenna Journal of Medical Biotechnology, 16(4), 279-283. |
Chicago | Shahriari M, Shafiee F, Moazen F, Mir Mohammad Sadeghi H. "Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains." Avicenna Journal of Medical Biotechnology 16, no. 4 (2024): 279-283. |
Harvard | Shahriari M et al. (2024) 'Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains', Avicenna Journal of Medical Biotechnology, 16(4), pp. 279-283. |
Vancouver | Shahriari M, Shafiee F, Moazen F, Mir Mohammad Sadeghi H. Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains. Avicenna Journal of Medical Biotechnology. 2024;16(4):279-283. |
BibTex | @article{ author = {Shahriari M and Shafiee F and Moazen F and Mir Mohammad Sadeghi H}, title = {Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains}, journal = {Avicenna Journal of Medical Biotechnology}, volume = {16}, number = {4}, pages = {279-283}, year = {2024} } |
RIS | TY - JOUR AU - Shahriari M AU - Shafiee F AU - Moazen F AU - Mir Mohammad Sadeghi H TI - Optimization of the Production of Soluble Recombinant Tev Protease in Two E. Coli Strains JO - Avicenna Journal of Medical Biotechnology VL - 16 IS - 4 SP - 279 EP - 283 PY - 2024 ER - |